NEFL and myeloid sarcoma: In summary, we perform the largest analysis of the plasma proteome in MS, replicating known biomarkers for diseases such as NFL and GFAP, suggesting plausible targets for therapeutic intervention, discovering a new disease‐specific negative biomarker (GZMA), and suggesting an association between plasma coagulation factors and MRI outcomes in MS.